PT2131860E - Anticorpos antiesclerostina - Google Patents

Anticorpos antiesclerostina Download PDF

Info

Publication number
PT2131860E
PT2131860E PT87319059T PT08731905T PT2131860E PT 2131860 E PT2131860 E PT 2131860E PT 87319059 T PT87319059 T PT 87319059T PT 08731905 T PT08731905 T PT 08731905T PT 2131860 E PT2131860 E PT 2131860E
Authority
PT
Portugal
Prior art keywords
sclerostin antibodies
sclerostin
antibodies
Prior art date
Application number
PT87319059T
Other languages
English (en)
Inventor
David Matthew Marquis
Barbara Anne Swanson
Andrew Ihor Korytko
Eric Michael Smith
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT2131860E publication Critical patent/PT2131860E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
PT87319059T 2007-03-20 2008-03-11 Anticorpos antiesclerostina PT2131860E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US89581307P 2007-03-20 2007-03-20

Publications (1)

Publication Number Publication Date
PT2131860E true PT2131860E (pt) 2014-03-04

Family

ID=39756356

Family Applications (1)

Application Number Title Priority Date Filing Date
PT87319059T PT2131860E (pt) 2007-03-20 2008-03-11 Anticorpos antiesclerostina

Country Status (32)

Country Link
US (3) US7744874B2 (pt)
EP (2) EP2664346A1 (pt)
JP (2) JP2010524846A (pt)
KR (1) KR101123487B1 (pt)
CN (1) CN101646457B (pt)
AU (1) AU2008229141B2 (pt)
BR (1) BRPI0809026A2 (pt)
CA (1) CA2682212C (pt)
CO (1) CO6230999A2 (pt)
CR (1) CR11004A (pt)
CY (1) CY1114784T1 (pt)
DK (1) DK2131860T3 (pt)
DO (1) DOP2009000223A (pt)
EA (1) EA018204B1 (pt)
EC (1) ECSP099658A (pt)
ES (1) ES2446293T3 (pt)
HK (1) HK1138790A1 (pt)
HR (1) HRP20140108T1 (pt)
IL (1) IL200437A0 (pt)
MA (1) MA31308B1 (pt)
MX (1) MX2009010051A (pt)
MY (1) MY149129A (pt)
NZ (1) NZ578870A (pt)
PL (1) PL2131860T3 (pt)
PT (1) PT2131860E (pt)
RS (1) RS53157B (pt)
SI (1) SI2131860T1 (pt)
SV (1) SV2009003374A (pt)
TN (1) TN2009000383A1 (pt)
UA (1) UA96474C2 (pt)
WO (1) WO2008115732A2 (pt)
ZA (1) ZA200906345B (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1721979T3 (da) 1998-11-27 2010-12-13 Ucb Pharma Sa Sammensætninger og fremgangsmåder til forøgelse af knoglemineralisering
US20040009535A1 (en) * 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
WO2005014650A2 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
US8461155B2 (en) * 2003-09-22 2013-06-11 University Of Connecticut Sclerostin and the inhibition of WNT signaling and bone formation
US7592429B2 (en) 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
ES2930183T3 (es) 2006-12-29 2022-12-07 Ossifi Mab Llc Métodos para alterar el crecimiento óseo mediante la administración del antagonista o agonista de Sost o Wise
JP2010524846A (ja) * 2007-03-20 2010-07-22 イーライ リリー アンド カンパニー 抗スクレロスチン抗体
CL2008002775A1 (es) * 2007-09-17 2008-11-07 Amgen Inc Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
AU2008338464A1 (en) * 2007-12-14 2009-06-25 Amgen Inc. Method for treating bone fracture with anti-sclerostin antibodies
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
CA2721052C (en) 2008-04-11 2023-02-21 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
WO2010115932A1 (en) 2009-04-08 2010-10-14 Novartis Ag Combination for the treatment of bone loss
BR112012025568A2 (pt) 2010-04-07 2017-03-28 Abbvie Inc proteínas de ligação ao tnf-<244>.
JP2013525294A (ja) 2010-04-16 2013-06-20 ノバルティス アーゲー インプラント骨結合を改善するための方法および組成物
ME02819B (me) 2010-05-14 2018-01-20 Amgen Inc Formulacije sa visokom koncentracijom antitijela
EP2579895A4 (en) * 2010-06-14 2013-12-18 Vaccinex Inc ANTI-VEGF ANTIBODIES AND USES THEREOF
DE20187001T1 (de) 2010-11-05 2021-04-01 Novartis Ag Verfahren zur behandlung von psoriasus-arthritis mit il-17 antagonisten
JP5319651B2 (ja) * 2010-11-18 2013-10-16 日本電信電話株式会社 分析方法
TWI654203B (zh) 2010-11-30 2019-03-21 中外製藥股份有限公司 具有鈣依存性的抗原結合能力之抗體
PL2663579T3 (pl) 2011-01-14 2017-09-29 The Regents Of The University Of California Przeciwciała terapeutyczne przeciwko białku receptorowemu ror 1 oraz sposoby ich stosowania
JP2014509588A (ja) 2011-03-01 2014-04-21 アムジエン・インコーポレーテツド 二特異性結合剤
KR20140018315A (ko) 2011-03-25 2014-02-12 암젠 인크 항스클러로스틴 항체 결정 및 이의 제제
RS57877B1 (sr) 2011-04-19 2018-12-31 Amgen Inc Metoda za lečenje osteoporoze
EP2702408A1 (en) 2011-04-29 2014-03-05 Novartis AG Methods of treating squamous cell carcinoma related applications
NO2739311T3 (pt) 2011-08-04 2018-07-21
KR20140084253A (ko) 2011-10-24 2014-07-04 애브비 인코포레이티드 Ｔｎｆ에 대한 면역결합제
PE20142245A1 (es) 2011-10-24 2015-01-22 Abbvie Inc Inmunoligantes biespecificos dirigidos contra tnf e il-17
CN104203978A (zh) 2011-10-24 2014-12-10 艾伯维股份有限公司 针对硬化蛋白的免疫结合剂
SG10201509629QA (en) 2011-12-28 2015-12-30 Amgen Inc Method Of Treating Alveolar Bone Loss Through The Use Of Anti-Sclerostin Antibodies
AU2013285488B2 (en) 2012-07-05 2018-03-22 Ucb Pharma S.A. Treatment for bone diseases
WO2014015133A1 (en) 2012-07-19 2014-01-23 National Cheng Kung University Treatment of osteoarthritis using il-20 antagonists
US20140065144A1 (en) * 2012-08-30 2014-03-06 National Cheng Kung University Use of il-20 antagonists for promoting bone fracture healing
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014118705A1 (en) 2013-01-31 2014-08-07 Novartis Ag Methods of treating chronic kidney disease-mineral and bone disorder using sclerostin antagonists
AR094877A1 (es) * 2013-03-08 2015-09-02 Lilly Co Eli Anticuerpos que se unen a il-23
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
WO2014155278A2 (en) 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2015087187A1 (en) 2013-12-10 2015-06-18 Rinat Neuroscience Corp. Anti-sclerostin antibodies
US9763911B2 (en) 2013-12-12 2017-09-19 Mayo Foundation For Medical Education And Research Prostacyclin compositions for regulation of fracture repair and bone formation
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
MA41101A (fr) * 2014-12-03 2017-10-10 Lilly Co Eli Dispositif d'injection de médicament automatique comportant une indication audible de progression d'injection
MA41142A (fr) 2014-12-12 2017-10-17 Amgen Inc Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
BR112017014258A2 (pt) * 2014-12-30 2018-03-06 Celgene Corp anticorpos anti-cd47 e usos dos mesmos
MX2017011480A (es) * 2015-03-13 2018-04-24 Jiangsu Hengrui Medicine Co Anticuerpo de anti-esclerostina, fragmento de union a antigeno y uso medico del mismo.
WO2017149538A1 (en) 2016-03-01 2017-09-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human poliovirus receptor (pvr)
GB201604124D0 (en) 2016-03-10 2016-04-27 Ucb Biopharma Sprl Pharmaceutical formulation
CN110214021A (zh) 2016-08-08 2019-09-06 安进公司 使用抗硬化蛋白抗体改善***附着的方法
MX2019004862A (es) * 2016-10-28 2019-08-12 Lilly Co Eli Anticuerpos anti-rankl y usos de los mismos.
AU2017354070A1 (en) * 2016-11-01 2019-05-16 Anaptysbio, Inc. Antibodies directed against programmed death- 1 (PD-1)
CA3047221A1 (en) * 2016-12-21 2018-06-28 Mereo Biopharma 3 Limited Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta
BR112019014187A2 (pt) 2017-01-09 2020-02-11 Tesaro, Inc. Métodos de tratamento de câncer com anticorpos anti-pd-1
EP3574010A4 (en) * 2017-01-30 2020-12-16 Chugai Seiyaku Kabushiki Kaisha ANTI-SCLEROSTIN ANTIBODIES AND METHOD OF USE
WO2018227187A1 (en) * 2017-06-09 2018-12-13 The Regents Of The University Of California Catheter injectable cyclic peptide pro-gelators for myocardial tissue engineering
US11498961B2 (en) * 2017-07-27 2022-11-15 Jiangsu Hengrui Medicine Co., Ltd. SOST antibody pharmaceutical composition and uses thereof
TW201942131A (zh) 2018-03-30 2019-11-01 美商安進公司 C末端抗體變體
GB201810746D0 (en) 2018-06-29 2018-08-15 Mereo Biopharma 3 Ltd Use of sclerostin antagonist
MX2021001554A (es) 2018-08-10 2021-04-13 Amgen Inc Metodo de preparacion de una formulacion farmaceutica de anticuerpos.
EP3883971A1 (en) * 2019-01-22 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
WO2021030179A1 (en) 2019-08-12 2021-02-18 Amgen Inc. Anti-sclerostin antibody formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1721979T3 (da) 1998-11-27 2010-12-13 Ucb Pharma Sa Sammensætninger og fremgangsmåder til forøgelse af knoglemineralisering
US20040009535A1 (en) 1998-11-27 2004-01-15 Celltech R&D, Inc. Compositions and methods for increasing bone mineralization
AU2001272482A1 (en) 2000-06-19 2002-01-02 F.Hoffmann-La Roche Ag Osteolevin gene polymorphisms
AU2003276430A1 (en) 2002-06-14 2003-12-31 Stowers Institute For Medical Research Wise/sost nucleic acid sequences and amino acid sequences
WO2004047609A2 (en) * 2002-11-27 2004-06-10 Visiopharm Aps A method and a system for establishing a quantity measure for joint destruction
WO2005014650A2 (en) 2003-06-16 2005-02-17 Celltech R & D, Inc. Antibodies specific for sclerostin and methods for increasing bone mineralization
WO2005005604A2 (en) 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
EP1853630A1 (en) 2004-10-22 2007-11-14 Applied Molecular Evolution Inc. Methods of optimizing antibody variable region binding affinity
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
EP2097450A2 (en) 2006-11-10 2009-09-09 Amgen Inc. Antibody-based diagnostics and therapeutics
JP2010524846A (ja) * 2007-03-20 2010-07-22 イーライ リリー アンド カンパニー 抗スクレロスチン抗体

Also Published As

Publication number Publication date
AU2008229141B2 (en) 2013-02-07
CA2682212C (en) 2014-05-06
US20100221263A1 (en) 2010-09-02
KR101123487B1 (ko) 2012-03-23
EP2131860B1 (en) 2013-12-18
US8257704B2 (en) 2012-09-04
HRP20140108T1 (hr) 2014-02-28
ECSP099658A (es) 2009-10-30
CY1114784T1 (el) 2016-12-14
EP2131860A2 (en) 2009-12-16
CR11004A (es) 2009-11-02
MX2009010051A (es) 2009-10-12
AU2008229141A1 (en) 2008-09-25
EA018204B1 (ru) 2013-06-28
SI2131860T1 (sl) 2014-02-28
ZA200906345B (en) 2010-11-24
CN101646457B (zh) 2013-05-01
KR20090114462A (ko) 2009-11-03
WO2008115732A3 (en) 2008-12-11
NZ578870A (en) 2012-01-12
SV2009003374A (es) 2011-01-10
US7988970B2 (en) 2011-08-02
UA96474C2 (en) 2011-11-10
US20110250205A1 (en) 2011-10-13
RS53157B (en) 2014-06-30
CO6230999A2 (es) 2010-12-20
JP2013151504A (ja) 2013-08-08
TN2009000383A1 (en) 2010-12-31
JP5758933B2 (ja) 2015-08-05
MA31308B1 (fr) 2010-04-01
CN101646457A (zh) 2010-02-10
JP2010524846A (ja) 2010-07-22
WO2008115732A2 (en) 2008-09-25
CA2682212A1 (en) 2008-09-25
EA200970874A1 (ru) 2010-02-26
US20090060924A1 (en) 2009-03-05
IL200437A0 (en) 2010-04-29
EP2664346A1 (en) 2013-11-20
BRPI0809026A2 (pt) 2014-09-23
US7744874B2 (en) 2010-06-29
PL2131860T3 (pl) 2014-05-30
DOP2009000223A (es) 2009-10-15
ES2446293T3 (es) 2014-03-07
DK2131860T3 (da) 2014-01-13
HK1138790A1 (en) 2010-09-03
MY149129A (en) 2013-07-15

Similar Documents

Publication Publication Date Title
HK1138790A1 (en) Anti-sclerostin antibodies
PT2195026E (pt) Anticorpos anti-esclerostina
IL229512A0 (en) Anti-vegf antibodies
GB0708002D0 (en) Antibodies
AP3371A (en) Anti-IGF antibodies
SI2200700T1 (sl) Nova protitelesa
ZA201005348B (en) Humanized anti-c5ar antibodies
EP2331579A4 (en) MONOCLONAL ANTIBODIES
HK1136970A1 (en) Penta-specific antibody
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
IL204835A0 (en) Humanized antibody
GB0821100D0 (en) Antibodies
IL200168A0 (en) Monoclonal anti-cxcl13 antibodies
EP2172483A4 (en) ANTI-MUC17 ANTIBODY
EP2259795A4 (en) ANTI-VEGF ANTIBODY
EP2337798A4 (en) BSA-SPECIFIC ANTIBODIES
GB0702888D0 (en) Novel Antibodies
GB0718737D0 (en) Antibodies
IL205073A0 (en) Anti-bst2 antibody
EP2160407A4 (en) NEUTRALIZING ANTIBODIES
ZA201006099B (en) Anti-tyrp1 antibodies
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
GB0724185D0 (en) Antibodies
GB0706965D0 (en) Humanized antibody